SCHEMBL3793294

SCHEMBL3793294

Cc1c(N)cccc1-c1ccc(N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.54
TSHR P16473 1/20 0.54
PIK3CA P42336 1/20 0.54
ALDH1A1 P00352 4/20 0.45
HSD17B10 Q99714 2/20 0.43
TDP1 Q9NUW8 2/20 0.42
TP53 P04637 1/20 0.42
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TAAR1 Q96RJ0 2/20 0.41
KIT P10721 2/20 0.41
KDR P35968 2/20 0.41
FLT3 P36888 2/20 0.41
ACHE P22303 2/20 0.40
BCHE P06276 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
RPS6KA3 P51812 1/20 0.39
CD274 Q9NZQ7 2/20 0.38
PDCD1 Q15116 1/20 0.38
CD44 P16070 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647993 0.87 CYP3A4 (0.54) CYP3A4TSHRPIK3CAALDH1A1HSD17B10
SCHEMBL365320 0.84 ALDH1A1 (0.62) CYP3A4TSHRPIK3CAALDH1A1HSD17B10
SCHEMBL29788122 0.84 ALDH1A1 (0.62) CYP3A4TSHRPIK3CAALDH1A1HSD17B10
SCHEMBL27553519 0.83 CYP3A4 (0.50) CYP3A4TSHRPIK3CAALDH1A1HSD17B10
SCHEMBL1461187 0.83 CYP3A4 (0.42) CYP3A4TSHRPIK3CAALDH1A1HSD17B10
SCHEMBL9650531 0.81 CYP3A4 (0.82) CYP3A4TSHRPIK3CAALDH1A1HSD17B10
SCHEMBL30839749 0.81 CYP3A4 (0.72) CYP3A4TSHRPIK3CAALDH1A1HSD17B10
SCHEMBL2206282 0.81 CYP3A4 (0.72) CYP3A4TSHRPIK3CAALDH1A1HSD17B10
SCHEMBL27553476 0.80 ABL1 (0.50) CYP3A4TSHRPIK3CAALDH1A1TDP1
SCHEMBL820321 0.80 RPS6KA3 (0.47) CYP3A4TSHRPIK3CAALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 CYP3A4 177/4885TSHR 1688/4885PIK3CA 2327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.